Clinical trials: Cardiovascular Event
Hypertension, Cardiovascular Diseases
OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study
The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of…
- Trial name
- NCT00134160
- Testing
- Olmesartan medoxomil, Calcium channel blockers (amlodipine, azelnidipine)
- Where
- 2 sites in Japan
- Volunteers
- 1,000 people
- Sponsor
- OSCAR Study
Heart Failure, Coronary Artery Disease
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and…
- Trial name
- COMMANDER HF (NCT01877915)
- Testing
- Rivaroxaban, Standard of care for heart failure and coronary artery disease
- Where
- 562 sites in United States, Argentina and 30 more
- Volunteers
- 5,081 people
- Sponsor
- Janssen Research & Development, LLC
Thrombosis, Stent Thrombosis
Evaluating Pharmacogenomic Variants for Cardiology Therapeutics
Cipherome's Lighthouse is a clinical decision support tool that incorporates a patient's pharmacogenetic information to determine therapeutic strategy, including determining appropriate dosage or assessing the likelihood of…
- Conditions
- Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction
- Trial name
- CARES2 (NCT04702113)
- Testing
- Cipherome Lighthouse Pilot
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Cipherome, Inc.
Lipoprotein Disorder
A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
The main purpose of this study is to evaluate the efficacy and safety of HRS-5632 in adult participants with elevated Lipoprotein(a) (Lp(a)) at high risk for cardiovascular events.
- Trial name
- NCT07185776
- Testing
- HRS-5632 Injection
- Where
- 2 sites in China
- Volunteers
- 203 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Heart Failure
Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)
This is a multicenter study to evaluate potential decrease in hospitalization events and time between events and increasing longevity in patients with symptomatic congestive heart failure and intolerant of first-line medication…
- Trial name
- NCT00090259
- Testing
- Losartan 50 mg, Losartan 150 mg
- Volunteers
- 3,834 people
- Sponsor
- Organon and Co
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-1 (NCT01975376)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,745 sites in United States, Argentina and 34 more
- Volunteers
- 16,784 people
- Sponsor
- Pfizer
Hypercholesterolemia, Type 2 Diabetes
Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments
The study is being conducted to compare the effect of standard treatment (target LDL-C level: <120 mg/dL (JASGL 2007 target level)) and intensive treatment (target LDL-C level: <70 mg/dL) in the prevention of major adverse…
- Conditions
- Hypercholesterolemia, Type 2 Diabetes, Hypertension
- Trial name
- POSITIVE (NCT01173939)
- Testing
- Pravastatin, Rosuvastatin
- Where
- 317 sites in Japan
- Volunteers
- 10,000 people
- Sponsor
- Positive Trial Group
Peripheral Vascular Diseases, Cardiovascular Diseases
Warfarin and Antiplatelet Vascular Evaluation
The purpose of this study is to evaluate whether the addition of warfarin (a blood-thinning medication) to an antiplatelet therapy like aspirin is better than antiplatelet therapy alone (i.e.
- Trial name
- NCT00125671
- Testing
- Warfarin
- Where
- Canada
- Volunteers
- 2,400 people
- Sponsor
- Anand, Sonia, M.D.
Arrhythmia, Children
Optimizing Diagnostics Of Arrhythmia Events In Children Using Intelligent Telemetric Solutions
The purpose of this study is to assess efficacy of prolonged Full Disclosure electrocardiogram (ECG) monitoring and signal analysis using advanced telemetric technology to diagnose arrhythmia in comparison with standard…
- Trial name
- TELEMARC2 (NCT01265771)
- Testing
- Prolonged telemetric Full Disclosure ECG recording., Repeated 24 hours ECG Holter monitoring
- Where
- 3 sites in Poland
- Volunteers
- 400 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Stroke, Stroke, Acute
Impact of COVID-19 Vaccines on Cerebrovascular Health
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may reduce the transmission of and achieve population immunity against the COVID-19 pandemic, which accounted for more than 3.75million…
- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic, Dementia
- Trial name
- NCT04992195
- Testing
- Laboratory tests and Montreal Cognitive Assessment
- Where
- Hong Kong
- Volunteers
- 415 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Atrial Fibrillation
Artificial Intelligence Models to Predict Clinically Relevant Cardiovascular Outcomes
Atrial fibrillation (AF) is a frequent and clinically relevant problem among the events that may occur during the hospitalization period in patients with cardiovascular disease.
- Trial name
- PERCARD (NCT06847100)
- Testing
- Blood withdrawal
- Where
- 4 sites in Finland, Germany and 1 more
- Volunteers
- 273 people
- Sponsor
- Centro Cardiologico Monzino
Major Adverse Cardiac Events, Cerebrovascular Accident
Construction of a Prediction Model for MACCE in Elderly Patients After Elective Non-cardiac Surgery
Severe cardiovascular and cerebrovascular complications, including cardiac death, non-fatal angina/myocardial infarction, non-fatal heart failure, stroke, severe arrhythmia, etc., are one of the main types of postoperative…
- Conditions
- Major Adverse Cardiac Events, Cerebrovascular Accident, Postoperative Complications, Models
- Trial name
- NCT06391632
- Testing
- Revised Cardiac Risk Index
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Cardiovascular Disease
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and…
- Trial name
- NCT07214857
- Where
- United States
- Volunteers
- 1,385 people
- Sponsor
- Novartis Pharmaceuticals
MACE, Atrial Fibrillation (AF)
throMboembolic Risk Associated To High atrIal Fibrillation riSk
Cardiovascular diseases are the leading cause of mortality from treatable conditions in the European Union and the second from preventable causes, with a standardized mortality rate of 257.8 deaths per 100,000 inhabitants.
- Conditions
- MACE, Atrial Fibrillation (AF), Quality-adjusted Life-years, Electronic Health Records
- Trial name
- MATHIAS (NCT07441759)
- Testing
- AI_MATHIAS
- Where
- Spain
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Atrial Fibrillation
A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World
The primary objectives of this study are to identify and diagnose Atrial Fibrillation (AF), evaluate improvement in cardiovascular (CV) outcomes, improve direct oral anti-coagulant (DOAC) adherence and persistence, and better…
- Trial name
- NCT04276441
- Testing
- Heart healthy Engagement Program with the Apple Watch Series 5 or later, Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later
- Where
- United States
- Volunteers
- 34,244 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Heart Failure, Right Ventricular Dysfunction
Mitigating Post-Op RV Dysfunction After LVAD Implantation
This project evaluates right ventricle (RV) protective strategies after left ventricular assist device (LVAD) implantation.
- Conditions
- Heart Failure, Right Ventricular Dysfunction, Right Ventricular Failure
- Trial name
- NCT05758194
- Testing
- Standardized RV Management, Usual Care RV Management
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Cardiovascular Diseases, Coronary Disease
Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)
To determine whether the addition of angiotensin converting enzyme (ACE) inhibitor to standard therapy in patients with known coronary artery disease and preserved left ventricular function will prevent cardiovascular mortality…
- Conditions
- Cardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial Infarction
- Trial name
- NCT00000558
- Testing
- angiotensin-converting enzyme inhibitors
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
COVID-19, Hemostasis
Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy
The understanding of haemostasis and inflammation cross-talk has gained considerable knowledge during the past decade in the field of arterial and venous thrombosis.
- Conditions
- COVID-19, Hemostasis, Coagulation
- Trial name
- THROMBCOVID2 (NCT04377490)
- Testing
- venous ultrasound, blood sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Polycythemia Vera
Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)
CYTO-PV is a phase III Prospective, Randomized, Open-label, with Blinded Endpoint evaluation (PROBE), multi-center, clinical trial in patients with diagnosis of Polycythemia vera (PV) treated at the best of recommended therapies…
- Trial name
- CYTO-PV (NCT01645124)
- Testing
- Hydroxyurea, Phlebotomy
- Where
- 26 sites in Italy
- Volunteers
- 365 people
- Sponsor
- Consorzio Mario Negri Sud
Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD).
- Trial name
- NCT07241390
- Testing
- Orforglipron
- Where
- 566 sites in Argentina, Australia and 36 more
- Volunteers
- 7,140 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.